drugset / Trial / NCT05951777
Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury
Phase 2
Recruiting
51 enrolled
Hope Biosciences LLC
The University of Texas Health Science Center, Houston · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The global objective of this study is to establish the safety and investigate the potential treatment effect of an intravenous infusion of HB-adMSCs (Hope Biosciences adipose-derived mesenchymal stem cells) on brain structure, neurocognitive/functional outcomes, and neuroinflammation after traumatic brain injury.
Timeline
- Start
- 2024-04-16
- Primary completion
- 2027-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HB-adMSCs | Cell therapy | 2e+08 cells | Intravenous |